Rasmus Blechingberg Friis

MD, Oncologist, PhD

Find me on Bluesky

[Rasmus Blechingberg Friis @Rbfriis]

The ProWide study has finally been published.
In a Danish population, remote ePRO-based symptom monitoring does not improve survival for patients with #lungcancer.
Should we reevaluate the expected clinical benefits of ePROs? @JCOOP_ASCO
https://t.co/80IKDW1LWT @cancer_dk

[Rasmus Blechingberg Friis @Rbfriis]

Find me on https://t.co/i5Z9gkenrS

#twitterisdead

[Rasmus Blechingberg Friis @Rbfriis]

Editorial comments on the ProWide study. I agree that clinical use of ePROs offers several important benefits beyond overall survival. #lungcancer https://t.co/4BfE0k4TxY

[OncoDaily @oncodaily]

Danish Melanoma Lifetime Achievement Award to Lars Bastholt - Danish Metastatic Melanoma Database
@RuhlmannC @DoniaMarco @Rbfriis

https://t.co/E8bgrNKhIH

#Cancer #OncoDaily #MedEd #MedX #MedNews #Medicine #Oncology #DAMMED

[Rasmus Blechingberg Friis @Rbfriis]

Great presentation at the annual Danish Melanoma Scientific Meeting by @OlofssonBagge about present and future surgical treatment of advanced melanoma

[Rasmus Blechingberg Friis @Rbfriis]

I don't think I've ever worked this hard on anything in my career.
The initial work for this study started back in 2016. Despite legal challenges with digital health data and the COVID-19 lockdown, we succeeded with a tremendous collaboratory effort in this Danish national RCT 🙂

[JCO Oncology Practice @JCOOP_ASCO]

Remote Symptom Monitoring of Patients With Advanced
Lung Cancer (The ProWide Study): A Randomized
Controlled Trial https://t.co/9PIiEj60zj

Authored by @rbfriis et al. #LungCancer #lcsm

[Stinus Lindgreen @stinuslindgreen]

Man bør anerkende, at der er områder, hvor mænd er særligt udsatte. Ligestillingen halter, når det for eksempel kommer til mænds mentale sundhed. Det har jeg skrevet om sammen med @SamiraNawa og en række aktører på området. #dkpol #sundpol

https://t.co/hfFpgpTQQy

[Rasmus Blechingberg Friis @Rbfriis]

@EthanBasch1 @Helle_PP @lisa_wintner @EORTC_QLG @madeline_pe @OncoAlert @OncBrothers @OncLive @VJOncology

[Rasmus Blechingberg Friis @Rbfriis]

The ProWide study has finally been published.
In a Danish population, remote ePRO-based symptom monitoring does not improve survival for patients with #lungcancer.
Should we reevaluate the expected clinical benefits of ePROs? @JCOOP_ASCO
https://t.co/80IKDW1LWT @cancer_dk

[Rasmus Blechingberg Friis @Rbfriis]

@EthanBasch1 @Helle_PP @lisa_wintner @EORTC_QLG @madeline_pe @OncoAlert @OncBrothers @OncLive @VJOncology

[Rasmus Blechingberg Friis @Rbfriis]

@RyanNipp @ASCO @JCO_ASCO @JCOOP_ASCO Thanks for sharing :-)

[Rasmus Blechingberg Friis @Rbfriis]

@oncology_bg Does DMFS correlate with OS in an adjuvant setting for pts with melanoma?

[Rasmus Blechingberg Friis @Rbfriis]

This is one of the greatest achievements in the history of cancer treatment. #melanoma #immunotherapy #esmo24 #cure

[NEJM @NEJM]

Original Article: Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/dcXkj4NQw7

#ESMO24 | @myESMO

[Roger Olofsson Bagge @OlofssonBagge]

@HildurHelg presents out Swedish data showing no OS benefit with adjuvant immunotherapy for stage III melanoma. #ESMO24

[ESMO - Eur. Oncology @myESMO]

#ESMO24: Questions remain on optimal #AdjuvantTherapy for advanced #melanoma. OS trial data are not yet available & #RealWorld data suggest that surrogate endpoints may not translate into OS benefit in clinical practice @TeresaSAmaral #ESMODailyReporter
📌https://t.co/QyA1zsbC7F

[Sumanta K. Pal, MD, FASCO @montypal]

Bravo! @ciccarese_c - beautiful presentation. Congrats to you, @DrIacovelli & the stellar team on intriguing data - a hugely important contribution to the emerging data on #microbiome modulation. Looking fwd to seeing next steps! #ESMO24

[Rasmus Blechingberg Friis @Rbfriis]

@DrIacovelli @weoncologists @ciccarese_c @gianluca1aniro @OncoAlert @Unicatt @nsegata @CPRT65 @ChristianHvas

[Rasmus Blechingberg Friis @Rbfriis]

Looking forward to #ESMO24 🙂

[Rasmus Blechingberg Friis @Rbfriis]

@matteolambe @AnnPartridgeMD @DanaFarber @myESMO @OncoAlert @YSCBuzz @TanjaSpanic What a wonderful presentation :-)

[Rasmus Blechingberg Friis @Rbfriis]

@ADMoller Hvad nu? Jeg kan ikke læse det. Jeg ved ikke om jeg orker flere politiske "nu viser jeg handlekraft-projekter"

[Vivek Subbiah, MD @VivekSubbiah]

Cardiotoxicity of Immune Checkpoint Inhibitors https://t.co/FrJuCtOz72